nevro - Search News

Nevro, Piper Sandler

Fintel reports that on February 7, 2025, Piper Sandler upgraded their outlook for Nevro (NYSE:NVRO) from Underweight to Neutral. Analyst Price Forecast Suggests 37.44% Upside As of January 28, 2025, the average one-year price target for Nevro is $7.

Investing.com on MSN · 1d

Piper Sandler raises Nevro stock to Neutral, cuts target to $5.85

Piper Sandler analyst Adam Maeder upgraded shares of Nevro Corp (NYSE:NVRO), a medical device company with a market capitalization of $214 million, to Neutral from Underweight and adjusted the price target to $5.

Business Insider · 1d

Nevro price target raised to $5.85 from $5 at Baird

Baird raised the firm’s price target on Nevro (NVRO) to $5.85 from $5 and keeps a Neutral rating on the shares. The firm noted its acquisition

Nevro, Globus

YAHOO!Finance · 1d

Globus Medical to Acquire Nevro in $250 Million Deal to Expand Chronic Pain Treatment Portfolio

Globus will buy all outstanding Nevro shares for $5.85 per share under the terms of the agreement, therefore reflecting a 27% premium over its 90-day volume-weighted average price and a 17% premium over its closing price on Feb.

MassDevice · 22h

Globus Medical to acquire Nevro for $250M

Globus Medical (NYSE:GMED) announced today that it agreed to acquire chronic pain treatment developer Nevro (NYSE:NVRO).

MarketWatch · 1d

Globus Medical to Acquire Nevro Corp. to Expand Treatment Options for Patients

Globus Medical (NYSE: GMED), a leading musculoskeletal solutions company, and Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain,

Zacks.com on MSN1d

Nevro (NVRO) Soars 13.9%: Is Further Upside Left in the Stock?

Nevro (NVRO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...

14h

Nevro upgraded to Hold from Underperform at Jefferies

Jefferies upgraded Nevro (NVRO) to Hold from Underperform with a price target of $5.85, up from $4.50, after the company entered into a ...

medtechdive1d

Globus to buy Nevro for $250M

Analysts said Nevro’s valuation was “inexpensive,” but the spinal cord stimulation business can benefit from Globus’ scale ...

Nasdaq15d

Here's Why you Should Add Nevro Stock to Your Portfolio Now

Nevro NVRO is well-poised for growth in the coming quarters, courtesy of its business expansion plans and restructuring activities. The optimism, led by a decent preliminary full-year 2024 ...

Globus acquisition of Nevro ‘fairly low-risk bet,’ says BTIG

BTIG says Globus Medical’s (GMED) announced acquisition of Nevro (NVRO) “is surprising on the surface.” Investors did not expect Globus would ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

Nevro, Piper Sandler

Nevro, Globus

Related topics